The consolidation of nanomedicine

Zingg, Raphael; Fischer, Marius

doi:10.1002/wnan.1569

Cited by 28 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 3 ] Thus, nowadays, with the requirements for more personalized treatments and precision medications, [ 4 ] the interest in these materials to develop multimodal/multifunctional nanosized particles that can perform diagnosis [ 5 ] and different therapies (such as chemo‐, thermo‐, radio‐, immunotherapies) in a single nanoplatform [ 6 ] is continuously growing. [ 7 ]…”

Section: Introductionmentioning

confidence: 99%

Cerium Oxide Nanoparticles: Advances in Biodistribution, Toxicity, and Preclinical Exploration

Casals

Zeng

Parra‐Robert

et al. 2020

Small

110

View full text Add to dashboard Cite

to contribute to improved treatments by the generation of new diagnostic and therapeutic products. In particular, inorganic nanoparticles (NPs) have emerged as flexible platforms to develop new imaging and therapy agents for detecting and treating diseases at its earliest stages, with benefits superior to any currently used treatments. [1] These materials have been reported as robust drug carriers, versatile scaffolds able to adjust conjugated biomolecules activity, and antennas that can be excited in biologically transparent media. [2] Besides, they can be easily detected and tracked in physiological environments due to their unique physicochemical signatures. [3] Thus, nowadays, with the requirements for more personalized treatments and precision medications, [4] the interest in these materials to develop multimodal/multifunctional nanosized particles that can perform diagnosis [5] and different therapies (such as chemo-, thermo-, radio-, immunotherapies) in a single nanoplatform [6] is continuously growing. [7] Among the broad range of newly proposed nanomaterials, antioxidant NPs add to this list of advantages that they even Antioxidant nanoparticles have recently gained tremendous attention for their enormous potential in biomedicine. However, discrepant reports of either medical benefits or toxicity, and lack of reproducibility of many studies, generate uncertainties delaying their effective implementation. Herein, the case of cerium oxide is considered, a well-known catalyst in the petrochemistry industry and one of the first antioxidant nanoparticles proposed for medicine. Like other nanoparticles, it is now described as a promising therapeutic alternative, now as threatening to health. Sources of these discrepancies and how this analysis helps to overcome contradictions found for other nanoparticles are summarized and discussed. For the context of this analysis, what has been reported in the liver is reviewed, where many diseases are related to oxidative stress. Since well-dispersed nanoparticles passively accumulate in liver, it represents a major testing field for the study of new nanomedicines and their clinical translation. Even more, many contradictory works have reported in liver either cerium-oxide-associated toxicity or protection against oxidative stress and inflammation. Based on this, finally, the intention is to propose solutions to design improved nanoparticles that will work more precisely in medicine and safely in society.

show abstract

Section: Introductionmentioning

confidence: 99%

Cerium Oxide Nanoparticles: Advances in Biodistribution, Toxicity, and Preclinical Exploration

Casals

Zeng

Parra‐Robert

et al. 2020

Small

110

View full text Add to dashboard Cite

show abstract

“…Aside from this, of particular interest to cancer treatment researchers, is the approval of Doxil ® [10] by the Food and Therapeutic Administration (FDA) as the first encapsulated therapeutic, which meant a step forward in the development of new treatments. In fact, it accelerated the registration and marketing approvals of key pharmaceuticals in developed countries [11]. Nanomedicine provides hope to improve current cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

Niza

Ocaña

Castro‐Osma

et al. 2021

Cancers

View full text Add to dashboard Cite

Many therapeutic agents have failed in their clinical development, due to the toxic effects associated with non-transformed tissues. In this context, nanotechnology has been exploited to overcome such limitations, and also improve navigation across biological barriers. Amongst the many materials used in nanomedicine, with promising properties as therapeutic carriers, the following one stands out: biodegradable and biocompatible polymers. Polymeric nanoparticles are ideal candidates for drug delivery, given the versatility of raw materials and their feasibility in large-scale production. Furthermore, polymeric nanoparticles show great potential for easy surface modifications to optimize pharmacokinetics, including the half-life in circulation and targeted tissue delivery. Herein, we provide an overview of the current applications of polymeric nanoparticles as platforms in the development of novel nanomedicines for cancer treatment. In particular, we will focus on the raw materials that are widely used for polymeric nanoparticle generation, current methods for formulation, mechanism of action, and clinical investigations.

show abstract

“…14,15 It can reach tumor cells in the vascular endothelial space and undergo a liquid-to-gas phase transition to enhance the ultrasound imaging, so it has been widely used in ultrasound molecular imaging. [16][17][18][19] You et al 20 Prepared a multifunctional Fe3O4-PFH/PLGA nanoparticle, which undergoes a phase change in the PFH core of highly focused ultrasound and can work in synergy with highintensity focused ultrasound to effectively improve the therapeutic effect of tumors. In this study, in vitro targeting experiments showed that many nanoparticles labeled with red fluorescence in the AP-GNP group were tightly attached to the cell membrane surface of MCF-7 labeled with green fluorescence, and some nanoparticles were swallowed.…”

Section: Discussionmentioning

confidence: 99%

Application of ultrasound molecular imaging based on compressed sensing reconstruction algorithm to phase change drug-loaded PLGA nanoparticles targeting breast cancer MCF-7 Cells

2021

View full text Add to dashboard Cite

Objectives: To study the ability of aptamer-modified nano-gold rods and liquid carbon-targeted PLGA nanoparticles to target in vitro using compressed sensing reconstruction algorithm, and observe the phenomenon of mediating ultrasound / photoacoustic imaging. Methods: PLGA nanoparticles were prepared by a double emulsification method, and the MUC1 aptamer was connected to the PLGA nanoparticles by the carbodiimide method to obtain an “aptamer-PLGA nanoparticle” targeted phase change contrast agent. Fluorescence microscopy was used to detect the in vitro targeting of breast cancer MCF-7 cells specifically identified by it, and three control groups were set up: the ordinary nanoparticle group, the aptamer interference group, and the HELA cell group. A photoacoustic instrument was used to observe the phenomenon of enhanced ultrasound / photoacoustic signal mediated in vitro. Results: Many targeted nanoparticles were clustered around MCF-7 cells and bound firmly, but no specific binding was observed in the non-targeted nanoparticles group, the aptamer interference group and the HELA cell group. After the targeted nanoparticle was excited by the photoacoustic instrument, the ultrasonic signal and the photoacoustic signal were significantly enhanced compared with before the excitation. Conclusion: The successfully prepared targeting nanoparticles have good targeting and specificity for breast cancer MCF-7 cells, and it has obvious effects on ultrasound / photoacoustic imaging, and has the potential to become a dual-mode ultrasound / photoacoustic targeted contrast agent. The various characteristics provide experimental basis for subsequent in vivo targeting experiments and are expected to become good target diagnostic molecular probes. doi: https://doi.org/10.12669/pjms.37.6-WIT.4852 How to cite this:You Y, Cheng W, Chen H. Application of ultrasound molecular imaging based on compressed sensing reconstruction algorithm to phase change drug-loaded PLGA nanoparticles targeting breast cancer MCF-7 Cells. Pak J Med Sci. 2021;37(6):1610-1614. doi: https://doi.org/10.12669/pjms.37.6-WIT.4852 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

The consolidation of nanomedicine

Cited by 28 publications

References 25 publications

Cerium Oxide Nanoparticles: Advances in Biodistribution, Toxicity, and Preclinical Exploration

Cerium Oxide Nanoparticles: Advances in Biodistribution, Toxicity, and Preclinical Exploration

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

Application of ultrasound molecular imaging based on compressed sensing reconstruction algorithm to phase change drug-loaded PLGA nanoparticles targeting breast cancer MCF-7 Cells

Contact Info

Product

Resources

About